JP2014098052A - Skin external preparation - Google Patents
Skin external preparation Download PDFInfo
- Publication number
- JP2014098052A JP2014098052A JP2014040542A JP2014040542A JP2014098052A JP 2014098052 A JP2014098052 A JP 2014098052A JP 2014040542 A JP2014040542 A JP 2014040542A JP 2014040542 A JP2014040542 A JP 2014040542A JP 2014098052 A JP2014098052 A JP 2014098052A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- effect
- improvement effect
- extract
- external preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Cosmetics (AREA)
Abstract
Description
本発明は特定の植物抽出物を含有する新規な皮膚外用剤に関する。さらに詳しくは、ホソバヒカゲスゲ（Carex humilis ）抽出物とアスコルビン酸またはその誘導体をそれぞれ特定量含有する皮膚外用剤に関する。本発明の皮膚外用剤は、肌のくすみ改善効果、美白効果、肌のキメ改善効果、ニキビ・吹き出物改善効果にいずれも優れている。 The present invention relates to a novel skin external preparation containing a specific plant extract. More specifically, the present invention relates to an external preparation for skin containing specific amounts of an extract of Carex humilis and ascorbic acid or a derivative thereof. The external preparation for skin of the present invention is excellent in skin dullness improving effect, whitening effect, skin texture improving effect, and acne / breakout improving effect.
皮膚は、表皮と真皮からなる組織であり、外界からの物理的あるいは化学的ストレスから身体を守るバリア機能を果たしている。皮膚の外側に存在する表皮は、基底層、有棘層、顆粒層、角層からなり、主に角化細胞から構成されている。基底膜で分裂した角化細胞は、分化・成熟を経て上層に移行し、外表面の角層まで達した後、脱落し、ターンオーバー（新陳代謝）を繰り返し、表皮を形成している。表皮のターンオーバーは、皮膚バリア能や水分量の保持等に関与している。
したがって、老化や外部ストレスによって、角化細胞の増殖・角化・脱落のターンオーバーが滞ると、肌荒れや乾燥肌などの原因となると考えられている。そのため、肌荒れや乾燥肌の予防・治療に、表皮角化細胞賦活剤が用いられている。
Skin is a tissue composed of epidermis and dermis, and functions as a barrier that protects the body from physical or chemical stress from the outside. The epidermis existing outside the skin consists of a basal layer, a spiny layer, a granule layer, and a stratum corneum, and is mainly composed of keratinocytes. The keratinocytes that have divided in the basement membrane move to the upper layer through differentiation and maturation, reach the outer layer of the horny layer, and then drop off and repeat turnover (metabolism) to form the epidermis. The epidermis turnover is involved in maintaining the skin barrier ability and moisture content.
Therefore, it is considered that if the turnover of keratinocyte proliferation, keratinization, or shedding is delayed due to aging or external stress, it may cause rough skin or dry skin. Therefore, epidermal keratinocyte activators are used for the prevention and treatment of rough skin and dry skin.
これまでに、表皮角化細胞賦活剤として、アルギン酸オリゴ糖又はその塩（特許文献１）、高級脂肪族炭化水素（特許文献２）、ニトロ化脂肪族炭化水素（特許文献３）、（−）−エピガロカテキン−３−ガレート（非特許文献１）などの化合物だけでなく、ハス胚芽抽出物（特許文献４）、ヒカゲノカズラ属抽出物（特許文献５）、タイソウ抽出物（特許文献６）などの植物抽出物についても報告されている。 So far, as an epidermal keratinocyte activator, alginic acid oligosaccharide or a salt thereof (Patent Document 1), higher aliphatic hydrocarbon (Patent Document 2), nitrated aliphatic hydrocarbon (Patent Document 3), (−) -Not only compounds such as epigallocatechin-3-gallate (Non-patent Document 1), but also a lotus germ extract (Patent Document 4), an extract of the genus Spiraea (Patent Document 5), a Tisoiso extract (Patent Document 6), etc. Some plant extracts have also been reported.
しかしながら、従来の表皮角化細胞賦活剤は、効果が充分でなかったり、配合量を上げると逆に効果が低下したりするなどの課題があり、皮膚外用剤に配合する際の用量に注意しなければならなかった。さらに、従来の表皮角化細胞賦活剤は、肌荒れ改善効果、保湿効果、肌のくすみ改善効果、美白効果、肌のキメ改善効果を有することが知られているが、ニキビ・吹き出物改善効果を有するものは知られていない。 However, conventional epidermal keratinocyte activators have problems such as insufficient efficacy or reduced effectiveness when the amount is increased. Pay attention to the dose when blended into a topical skin preparation. I had to. Furthermore, the conventional epidermal keratinocyte activator is known to have rough skin improvement effect, moisturizing effect, skin dullness improvement effect, whitening effect, skin texture improvement effect, but has acne / breakout improvement effect Things are not known.
本発明の目的は、肌のくすみ改善効果、美白効果、肌のキメ改善効果のみならず、ニキビ・吹き出物改善効果をも優位に有する皮膚外用剤を提供することである。 An object of the present invention is to provide a skin external preparation having not only a dull skin improvement effect, a whitening effect, and a skin texture improvement effect, but also an acne / pimple improvement effect.
本発明者らは、上記課題を解決するために、表皮ターンオーバー促進作用に関与する角化細胞賦活作用について、様々な植物抽出物を用いて鋭意研究を重ねてきた。その結果、ホソバヒカゲスゲ抽出物が高活性の表皮角化細胞賦活作用を有することを見出した。また、ホソバヒカゲスゲ抽出物と、アスコルビン酸またはその誘導体とをそれぞれ特定量含有させることによって、肌のくすみ改善効果、美白効果、肌のキメ改善効果のみならず、ニキビ・吹き出物改善効果という従来の表皮角化細胞賦活剤では得られなかった効果を有することを見出し、本発明を完成させるに至った。 In order to solve the above-mentioned problems, the present inventors have made extensive studies using various plant extracts on the keratinocyte activation action involved in the epidermal turnover promoting action. As a result, it has been found that the extract of Lilium japonica has a highly active epidermal keratinocyte activation effect. In addition, by adding a specific amount of the extract of Asperbic acid or ascorbic acid or a derivative thereof, not only the skin dullness improvement effect, the whitening effect, the skin texture improvement effect, but also the conventional epidermis such as an acne / pimple improvement effect It discovered that it had the effect which was not obtained with the keratinocyte activator, and came to complete this invention.
すなわち、本発明は、ホソバヒカゲスゲ（Carex humilis ）抽出物を乾燥残留物として０．０００１〜５質量％含有し、アスコルビン酸、その水溶性塩誘導体、そのエステル誘導体、そのエーテル誘導体、またはアスコルビン酸配糖体を０. ０００１〜５質量％含有する皮膚外用剤である。 That is, the present invention contains 0.0001 to 5% by mass of Carex humilis extract as a dry residue, and contains ascorbic acid, a water-soluble salt derivative thereof, an ester derivative thereof, an ether derivative thereof, or an ascorbic acid mixture. It is a skin external preparation containing 0.0001 to 5% by mass of a saccharide.
ホソバヒカゲスゲ（Carex humilis ）は、カヤツリグサ科スゲ属の多年草であり、北東アジア全体に分布する植物である。ホソバヒカゲスゲ抽出物についてはすでに、５α−レダクターゼ阻害作用（特許文献７）、ホルモンバランスが崩れた肌用スキンケア成分（特許文献８）、老化遅延用化粧品組成物（特許文献９）、チロシナーゼ阻害作用による美白効果（特許文献１０）、抗炎症作用（非特許文献２）についての報告がある。
しかしながら、ホソバヒカゲスゲ抽出物が高活性な表皮角化細胞賦活作用を有すること、また、ホソバヒカゲスゲ抽出物とアスコルビン酸またはその誘導体を皮膚外用剤にそれぞれ特定量含有させることによって、肌のくすみ改善効果、美白効果、肌のキメ改善効果のみならず、ニキビ・吹き出物改善効果が得られることは、未だ報告されていない。
Carex humilis is a perennial plant belonging to the genus Spodoptera, and is a plant distributed throughout Northeast Asia. As for the extract of the mosquito lizard, 5α-reductase inhibitory action (Patent Document 7), skin care ingredient for skin with broken hormone balance (Patent Document 8), cosmetic composition for delayed aging (Patent Document 9), tyrosinase inhibitory action There are reports on whitening effect (Patent Document 10) and anti-inflammatory action (Non-Patent Document 2).
However, Hosoba lizard extract has a highly active epidermal keratinocyte activating effect, and the skin dullness improving effect by containing specific amounts of Hosoba lizard extract and ascorbic acid or its derivatives in skin external preparations, respectively. It has not yet been reported that not only a whitening effect and a skin texture improving effect, but also an acne / pimple improvement effect can be obtained.
本発明の皮膚外用剤は、肌のくすみ改善効果、美白効果、肌のキメ改善効果のみならず、ニキビ・吹き出物改善効果をも優位に有するものであり、さらに経時安定性に優れるという効果を有する。 The external preparation for skin of the present invention has not only a dull skin improvement effect, a whitening effect and a skin texture improvement effect, but also has an effect of improving acne and pimples, and has an effect of being excellent in stability over time. .
以下、本発明について詳細に説明する。
本発明の皮膚外用剤はホソバヒカゲスゲ抽出物を含有する。まず、ホソバヒカゲスゲ抽出物について説明する。
Hereinafter, the present invention will be described in detail.
The external preparation for skin of the present invention contains the extract of Hosoba lizard. First, the Hosoba lizard extract will be described.
〔ホソバヒカゲスゲ抽出物〕
本発明に用いられるホソバヒカゲスゲ抽出物は、カヤツリグサ科スゲ属に属するホソバヒカゲスゲ（Carex humilis ）の根、葉、花、種子（中でも好ましくは根）を、そのままもしくは乾燥させた後、各種溶媒にて抽出したものであり、抽出液そのもの、もしくはその希釈物や濃縮物をいう。
[Hosoba lizard extract]
The extract of the squirrel lizard used in the present invention is the root, leaf, flower, or seed (particularly preferably the root) of the sedge genus Carex humilis belonging to the genus Spodoptera (Carex humilis). It is extracted and refers to the extract itself, or its dilution or concentrate.
抽出に用いられる溶媒としては、炭化水素、エステル、ケトン、エーテル、ハロゲン化炭化水素、水溶性のアルコール類及び水などが挙げられる。中でも好ましくは水、低級アルコール、多価アルコールの１種または２種以上を用いたものであり、更に好ましくは水、エタノール、１，３−ブチレングリコールの１種または２種以上を用いたものである。 Examples of the solvent used for extraction include hydrocarbons, esters, ketones, ethers, halogenated hydrocarbons, water-soluble alcohols and water. Among them, preferred are those using one or more of water, lower alcohol and polyhydric alcohol, and more preferred are those using one or more of water, ethanol and 1,3-butylene glycol. is there.
抽出方法は常法に従い、ホソバヒカゲスゲをそのまま、もしくは乾燥させた後、１種または２種以上の溶媒に１時間以上浸漬し、ろ過することで目的の抽出物を得ることができる。抽出は、常圧または加圧、減圧下で、室温または加熱、冷却下で行うことができる。さらに、二酸化炭素などを利用した超臨界抽出法や亜臨界抽出法、水蒸気蒸留など蒸留を用いて抽出する方法、ホソバヒカゲスゲを圧搾して抽出する方法、還流抽出法なども利用することができる。得られた抽出液は、溶媒留去により濃縮したり、カラムクロマトグラフィーや溶媒分画等の処理により精製しても良い。 The extraction method is in accordance with a conventional method, and the target extract can be obtained by immersing and filtering one or two or more solvents for 1 hour or more after drying the dried sow beetle as it is or after drying. Extraction can be carried out at normal pressure or under pressure, under reduced pressure, at room temperature or under heating and cooling. Furthermore, a supercritical extraction method using carbon dioxide or the like, a subcritical extraction method, a method of extraction using distillation such as steam distillation, a method of pressing and extracting scallops, a reflux extraction method, or the like can also be used. The obtained extract may be concentrated by distilling off the solvent, or purified by treatment such as column chromatography or solvent fractionation.
〔皮膚外用剤〕
本発明の皮膚外用剤は、上記ホソバヒカゲスゲ抽出物を乾燥残留物として０．０００１〜５質量％含有するものである。本発明における乾燥残留物の質量は、実際に溶媒を除去して乾燥させた残留物の質量のみならず、残留物に含まれる溶媒量を算出し、その溶媒量を減じた残留物の質量も概念的に包含される。例えば、抽出溶媒が揮発性である場合は、抽出溶媒を１０５℃〜１２０℃で完全に留去させ、残存した固形分の質量であり、抽出溶媒が不揮発性である場合は、高速液体クロマトグラフィー等で溶媒量を定量し、それ以外の成分量が乾燥残留物の質量である。
[Skin external preparation]
The external preparation for skin according to the present invention contains 0.0001 to 5% by mass of the above-mentioned Hosoba lizard extract as a dry residue. The mass of the dry residue in the present invention is not only the mass of the residue actually dried after removing the solvent, but also the mass of the residue obtained by calculating the amount of solvent contained in the residue and subtracting the amount of the solvent. Conceptually included. For example, when the extraction solvent is volatile, the extraction solvent is completely distilled off at 105 ° C. to 120 ° C., and is the mass of the remaining solid content. When the extraction solvent is nonvolatile, high performance liquid chromatography The amount of the solvent is quantified by, for example, and the amount of other components is the mass of the dry residue.
ホソバヒカゲスゲ抽出物の配合量は、乾燥残留物として０．０００１〜５質量％であり、好ましくは０．０００５〜２．５質量％であり、更に好ましくは０．００１〜１質量％である。配合量が０．０００１質量％未満では肌のくすみ改善効果、美白効果、肌のキメ改善効果、ニキビ・吹き出物改善効果を発揮することができず、５％質量を越えると製剤の安定性に問題が生じ易くなり好ましくない。 The blending amount of Hosoba lizard extract is 0.0001 to 5% by mass as a dry residue, preferably 0.0005 to 2.5% by mass, and more preferably 0.001 to 1% by mass. If the blending amount is less than 0.0001% by mass, the skin dullness improvement effect, whitening effect, skin texture improvement effect, acne / pimple improvement effect cannot be exhibited, and if it exceeds 5% mass, the stability of the preparation is problematic. Is likely to occur, which is not preferable.
本発明の皮膚外用剤は、さらに、アスコルビン酸またはその誘導体を０. ０００１〜５質量％含有する。アスコルビン酸の誘導体としては、例えば、アルカリ金属塩、アルカリ土類金属塩等の水溶性塩誘導体や、脂肪酸エステル、リン酸エステル、硫酸エステル等のエステル誘導体、アスコルビン酸配糖体、アルキルエーテル等のエーテル誘導体などが挙げられる。中でも好ましくはエステル誘導体、エーテル誘導体であり、さらに好ましくはエステル誘導体である。アスコルビン酸またはその誘導体の配合量は０. ０００１〜５質量％であり、好ましくは０．０００５〜２．５質量％であり、更に好ましくは０．００１〜１質量％である。０. ０００１〜５質量％を含有させることで、ホソバヒカゲスゲ抽出物との相乗的な効果が認められるようになり、その結果、肌のくすみ改善効果、美白効果、肌のキメ改善効果、ニキビ・吹き出物改善効果を優位に有する皮膚外用剤が得られる。 The external preparation for skin of the present invention further contains 0.0001 to 5% by mass of ascorbic acid or a derivative thereof. Examples of ascorbic acid derivatives include water-soluble salt derivatives such as alkali metal salts and alkaline earth metal salts, ester derivatives such as fatty acid esters, phosphate esters and sulfate esters, ascorbic acid glycosides, alkyl ethers and the like. And ether derivatives. Of these, ester derivatives and ether derivatives are preferable, and ester derivatives are more preferable. The compounding quantity of ascorbic acid or its derivative is 0.0001-5 mass%, Preferably it is 0.0005-2.5 mass%, More preferably, it is 0.001-1 mass%. By containing 0.0001 to 5% by mass, a synergistic effect with the extract of Lily is found, and as a result, skin dullness improvement effect, whitening effect, skin texture improvement effect, acne, An external preparation for skin having a superior breakthrough improvement effect is obtained.
本発明の皮膚外用剤は、様々な剤形にて調製することができ、例えば、化粧水、乳液、クリーム、ジェル、美容液、パック、オイル、軟膏、スプレー、貼付剤などとして利用することができる。本発明においては、化粧料や医薬品等の皮膚外用剤に常用されている添加物を、本発明の効果を損なわない範囲で、適宜配合することも可能である。 The external preparation for skin of the present invention can be prepared in various dosage forms. For example, it can be used as a lotion, milky lotion, cream, gel, cosmetic liquid, pack, oil, ointment, spray, patch, etc. it can. In the present invention, additives commonly used in external preparations for skin such as cosmetics and pharmaceuticals can be appropriately blended as long as the effects of the present invention are not impaired.
以下、実施例により本発明を更に詳細に説明するが、本発明は下記実施例に制限されるものではない。なお、特に断りのない限り、％は質量％を表す。 EXAMPLES Hereinafter, although an Example demonstrates this invention further in detail, this invention is not restrict | limited to the following Example. Unless otherwise indicated,% represents mass%.
〔ホソバヒカゲスゲ抽出物の調製〕
採取したホソバヒカゲスゲ根を純水で洗浄し乾燥させたもの５０ｇに、５００ｇの７０％エタノール水溶液を加え２４時間浸漬し抽出した。ろ過後、得られた抽出物を脱臭・脱色処理し、さらに濃縮することによりホソバヒカゲスゲ抽出物粉末を得た。
[Preparation of Hosoba lizard extract]
500 g of a 70% aqueous ethanol solution was added to 50 g of the collected roots of the mosquito, washed with pure water and dried, and extracted by immersion for 24 hours. After filtration, the obtained extract was deodorized and decolored, and further concentrated to obtain a powder of the extract of Lilium fountain.
〔参考例１、参考比較例１：表皮角化細胞賦活試験〕
上記のホソバヒカゲスゲ抽出物粉末と、（−）−エピガロカテキン−３−ガレート（和光純薬社製）をそれぞれ８０％エタノール水溶液で10mg／mLになるように溶解し、試験に供した。
マウス表皮角化細胞Ｐａｍ２１２を96ウェルプレートに2.0×10４cells／100μＬ／wellになるように播種した。播種培地はダルベッコ変法イーグル培地（Dalbecco’s Modified Eagle Medium, DMEM 和光純薬）に牛胎児血清（Biowest 社製）を終濃度10％になるように添加し、さらに終濃度100Ｕ／mLのペニシリン・ストレプトマイシン（GIBCO社製）を使用した。37℃、5％ＣＯ２下で24時間培養後、培地を除去し各濃度の試料を含む低血清培地（1％ＦＢＳ／ＤＭＥＭ）に置換し、72時間培養した。培養後、ＭＴＴアッセイにてミトコンドリア活性を測定し、表皮角化細胞賦活作用とした。ＭＴＴアッセイにより生成したホルマザンの量を570nmと630nmの吸光度の差として算出し、細胞賦活率は以下の式を用いて算出した。結果を表１に示す。細胞賦活率120％以上で有効と判定した。
細胞賦活率＝（Ａ570 −Ａ630 ）sample／（Ａ570 −Ａ630 ）control ×100（％）
[Reference Example 1, Reference Comparative Example 1: Epidermal keratinocyte activation test]
The above-mentioned Hosoba lizard extract powder and (−)-epigallocatechin-3-gallate (manufactured by Wako Pure Chemical Industries, Ltd.) were each dissolved in an 80% aqueous ethanol solution so as to be 10 mg / mL, and used for the test.
Mouse epidermal keratinocytes Pam212 were seeded in a 96-well plate at 2.0 × 10 4 cells / 100 μL / well. For seeding medium, fetal bovine serum (Biowest) was added to Dulbecco's Modified Eagle Medium (DMEM Wako Pure Chemical Industries) to a final concentration of 10%, and penicillin / streptomycin with a final concentration of 100 U / mL. (Manufactured by GIBCO) was used. After culturing at 37 ° C. and 5% CO 2 for 24 hours, the medium was removed and replaced with a low-serum medium (1% FBS / DMEM) containing each concentration of sample and cultured for 72 hours. After culturing, mitochondrial activity was measured by MTT assay to activate the keratinocytes. The amount of formazan produced by the MTT assay was calculated as the difference in absorbance between 570 nm and 630 nm, and the cell activation rate was calculated using the following formula. The results are shown in Table 1. The cell activation rate was judged to be effective at 120% or more.
Cell activation rate = (A570−A630) sample / (A570−A630) control × 100 (%)
表１の結果から、ホソバヒカゲスゲ抽出物は、従来の表皮角化細胞賦活剤として用いられている化合物よりも優れた表皮角化細胞賦活作用を示し、また高濃度においても賦活活性を示すことが明らかとなった。 From the results shown in Table 1, it can be seen that the extract of Lilium medulla exhibits an keratinocyte activation action superior to the compounds used as conventional keratinocyte activators, and also exhibits an activation activity even at high concentrations. It became clear.
〔実施例１、２、比較例１、２、３、４：官能評価〕
上記の表皮角化細胞賦活試験に供したホソバヒカゲスゲ抽出物の８０％エタノール水溶液、アスコルビン酸誘導体、（−）−エピガロカテキン−３−ガレートを使用して、表２に示す化粧水（皮膚外用剤）を調製し、５項目について下記評価基準により評価を行なった。結果を表２に示す。
[Examples 1 and 2, Comparative Examples 1, 2, 3, and 4: Sensory evaluation]
Using the 80% ethanol aqueous solution, ascorbic acid derivative, (−)-epigallocatechin-3-gallate of the extract of Lilium medaka, which was subjected to the above-mentioned epidermal keratinocyte activation test, Agent) was prepared, and 5 items were evaluated according to the following evaluation criteria. The results are shown in Table 2.
（評価項目及び評価基準）
（１）肌のくすみ改善効果
２０名の女性（３８才〜６３才）をパネラーとし、皮膚外用剤を１日２回、４週間使用後の肌の状態について下記のように官能評価を行った。
２点：明らかに肌のくすみが改善してきたと感じた場合。
１点：やや肌のくすみが改善してきたと感じた場合。
０点：肌に変化を感じなかった、また肌のくすみが悪化したと感じた場合。
(Evaluation items and evaluation criteria)
(1) Skin dullness improvement effect 20 females (38 to 63 years old) were panelists, and the skin condition after using a topical skin preparation twice a day for 4 weeks was subjected to sensory evaluation as follows. .
2 points: When the skin dullness is clearly improved.
1 point: When it feels that the dullness of the skin has improved a little.
0 point: When the skin did not feel change, and when the skin dullness was felt worse.
さらに、２０名の評価を加算し、合計点を下記の基準で判定した。
◎：３５点以上（非常に優れた肌のくすみ改善作用を有する皮膚外用剤）
○：３０点以上３５点未満（優れた肌のくすみ改善作用を有する皮膚外用剤）
△：１５点以上３０点未満（わずかに肌のくすみ改善作用を有する皮膚外用剤）
×：１５点未満（肌のくすみ改善作用を有しない皮膚外用剤）
Furthermore, the evaluation of 20 persons was added and the total score was determined according to the following criteria.
A: 35 or more (external preparation for skin with excellent skin dullness improving effect)
○: 30 points or more and less than 35 points (external skin preparation having excellent skin dullness improving effect)
Δ: 15 points or more and less than 30 points (skin external preparation having a slight skin dullness improving effect)
X: Less than 15 points (external preparation for skin having no skin dullness improving effect)
（２）美白効果
２０名の女性（３８才〜６３才）をパネラーとし、皮膚外用剤を１日２回、４週間使用した後の肌の状態について下記のように官能評価を行った。
２点：明らかに肌のシミ・そばかすが薄くなったと感じた場合。
１点：やや肌のシミ・そばかすが薄くなったと感じた場合。
０点：肌に変化を感じなかった、またはシミ・そばかすが増えたと感じた場合。
(2) Whitening effect Twenty women (38 to 63 years old) were used as panelists, and the skin condition after using the external preparation for skin twice a day for 4 weeks was subjected to sensory evaluation as follows.
2 points: When the skin spots and freckles clearly feel thin.
1 point: When the skin spots and freckles feel slightly thinner.
0 points: When the skin did not change, or when it felt that the freckles and freckles increased.
さらに、２０名の評価を加算し、合計点を下記の基準で判定した。
◎：３５点以上（非常に優れた美白作用を有する皮膚外用剤）
○：３０点以上３５点未満（優れた美白作用を有する皮膚外用剤）
△：１５点以上３０点未満（わずかに美白作用を有する皮膚外用剤）
×：１５点未満（美白作用を有しない皮膚外用剤）
Furthermore, the evaluation of 20 persons was added and the total score was determined according to the following criteria.
A: 35 points or more (external skin preparation having a very excellent whitening effect)
○: 30 points or more and less than 35 points (external skin preparation having excellent whitening effect)
Δ: 15 points or more and less than 30 points (skin external preparation having a slight whitening effect)
X: Less than 15 points (external preparation for skin having no whitening effect)
（３）肌のキメ改善効果
２０名の女性（３８才〜６３才）をパネラーとし、皮膚外用剤を１日２回、４週間使用した後の肌の状態について下記のように官能評価を行った。
２点：肌のキメが明らかに改善されたと感じた場合。
１点：肌のキメがやや改善されたと感じた場合。
０点：肌のキメに変化を感じない、またはキメが悪化したと感じた場合。
(3) Skin texture improvement effect 20 females (38 to 63 years old) are panelists, and the skin condition after using a topical skin preparation twice a day for 4 weeks is evaluated as follows. It was.
2 points: When the skin texture is clearly improved.
1 point: When the skin texture is slightly improved.
0 point: When the skin texture does not change, or when the texture feels worse.
さらに、２０名の評価を加算し、合計点を下記の基準で判定した。
◎：３５点以上（非常に優れた肌のキメ改善作用を有する皮膚外用剤）
○：３０点以上３５点未満（優れた肌のキメ改善作用を有する皮膚外用剤）
△：１５点以上３０点未満（わずかに肌のキメ改善作用を有する皮膚外用剤）
×：１５点未満（肌のキメ改善作用を有しない皮膚外用剤）
Furthermore, the evaluation of 20 persons was added and the total score was determined according to the following criteria.
A: 35 or more (external preparation for skin having a very excellent skin texture improving effect)
○: 30 points or more and less than 35 points (external preparation for skin having excellent skin texture improving effect)
Δ: 15 points or more and less than 30 points (external preparation for skin having slight skin texture improving effect)
X: Less than 15 points (external preparation for skin having no skin texture improving effect)
（４）ニキビ・吹き出物改善効果
ニキビや吹き出物に悩む２０名の男女（１８〜３２才）をパネラーとし、皮膚外用剤を１日２回、４週間使用後の肌の状態について下記のように官能評価を行った。
２点：明らかにニキビ・吹き出物が改善してきたと感じた場合。
１点：ややニキビ・吹き出物が改善してきたと感じた場合。
０点：肌に変化を感じなかった、またはニキビ・吹き出物が悪化したと感じた場合。
(4) Acne and pimples improvement effect 20 males and females (18-32 years old) who are suffering from acne and pimples are panelists, and the skin condition after using a topical skin preparation twice a day for 4 weeks is as follows. Evaluation was performed.
2 points: When it is apparent that acne and breakout have improved.
1 point: If you feel that acne and breakout have improved a little.
0 point: When the skin did not change, or when the acne / pimple was felt worse.
さらに、２０名の評価を加算し、合計点を下記の基準で判定した。
◎：３５点以上（非常に優れたニキビ・吹き出物改善作用を有する皮膚外用剤）
○：３０点以上３５点未満（優れたニキビ・吹き出物改善作用を有する皮膚外用剤）
△：１５点以上３０点未満（わずかにニキビ・吹き出物改善作用を有する皮膚外用剤）
×：１５点未満（ニキビ・吹き出物改善作用を有しない皮膚外用剤）
Furthermore, the evaluation of 20 persons was added and the total score was determined according to the following criteria.
A: 35 points or more (external skin preparation with very good acne / pimple improvement effect)
○: 30 points or more and less than 35 points (external skin preparation with excellent acne / pimple improvement effect)
Δ: 15 points or more and less than 30 points (external preparation for skin having a slight acne / pimple improvement effect)
X: Less than 15 points (external preparation for skin having no acne / pimple improvement effect)
（５）経時安定性
化粧料を透明ガラス容器に密封して０℃、２５℃、４０℃でそれぞれ３ヶ月間保存し、その外観を観察して、下に示す２段階で評価した。
○：安定性良好（いずれの温度においても外観の変化がない。）
×：安定性不良（いずれかの温度において、沈殿を生じるまたは分離する。もしくは変色を生じる。）
(5) Stability over time The cosmetic was sealed in a transparent glass container and stored at 0 ° C., 25 ° C., and 40 ° C. for 3 months. The appearance was observed and evaluated in two stages as shown below.
○: Good stability (no change in appearance at any temperature)
X: poor stability (precipitation occurs or separates at any temperature, or discoloration occurs)
実施例１、２の結果から、本発明によるホソバヒカゲスゲ抽出物とアスコルビン酸誘導体を併用した化粧水は、肌のくすみ改善効果、美白効果、肌のキメ改善効果、ニキビ・吹き出物改善効果に優れ、製剤の安定性も良好であることが理解できる。 From the results of Examples 1 and 2, the lotion combined with the ascorbic acid derivative according to the present invention is excellent in skin dullness improvement effect, whitening effect, skin texture improvement effect, acne / pimple improvement effect, It can be seen that the stability of the formulation is also good.
一方、本発明によるホソバヒカゲスゲ抽出物の成分を含有していない比較例１では、肌のくすみ改善効果、美白効果、肌のキメ改善効果、ニキビ・吹き出物改善効果は認められなかった。また、ホソバヒカゲスゲ抽出物のみを配合した比較例２では、肌のくすみ改善効果、美白効果、肌のキメ改善効果、ニキビ・吹き出物改善効果は認められるものの、いずれも十分なものではなかった。さらに、アスコルビン酸誘導体のみを含有する比較例３、公知の表皮細胞賦活剤である（−）−エピガロカテキン−３−ガレートを配合した比較例４においても、肌のくすみ改善効果、美白効果、肌のキメ改善効果、ニキビ・吹き出物改善効果はいずれも認められなかった。 On the other hand, in Comparative Example 1 which does not contain the component of the extract of the scabbard extract according to the present invention, no skin dullness improving effect, whitening effect, skin texture improving effect, acne / pimple improvement effect was not observed. Further, in Comparative Example 2 in which only the Hosobahikage extract was blended, skin dullness improvement effect, whitening effect, skin texture improvement effect, and acne / pimple improvement effect were recognized, but none of them was sufficient. Furthermore, in Comparative Example 3 containing only an ascorbic acid derivative, and in Comparative Example 4 in which (-)-epigallocatechin-3-gallate, which is a known epidermal cell activator, was added, skin dullness improving effect, whitening effect, Neither skin texture improvement effect nor acne / breakout improvement effect was observed.
〔実施例３、４、比較例５、６、７、８：官能評価〕
上記のホソバヒカゲスゲ抽出物粉末、アスコルビン酸誘導体、（−）−エピガロカテキン−３−ガレートを使用して、表３に示す乳液（皮膚外用剤）を調製し、実施例１、２と同様の方法により評価を行なった。なお、ホソバヒカゲスゲ抽出物を含有する乳液の調製は、ホソバヒカゲスゲ抽出物粉末を表３に示す多価アルコールとノニオン性界面活性剤成分にあらかじめ溶解した後、他の成分に配合することにより行った。結果を表３に示す。
[Examples 3 and 4, Comparative Examples 5, 6, 7, and 8: Sensory evaluation]
Using the above-mentioned powdered extract of lysopodum, ascorbic acid derivative, (−)-epigallocatechin-3-gallate, the emulsions (skin preparations for external use) shown in Table 3 were prepared, and the same as in Examples 1 and 2 Evaluation was performed by the method. In addition, preparation of the emulsion containing Hosoba lizard extract was carried out by previously dissolving Hosoba lizard extract powder in polyhydric alcohol and nonionic surfactant components shown in Table 3 and then blending with other components. . The results are shown in Table 3.
実施例３、４の結果から、本発明によるホソバヒカゲスゲ抽出物とアスコルビン酸誘導体を併用した乳液は、肌のくすみ改善効果、美白効果、肌のキメ改善効果、ニキビ・吹き出物改善効果に優れ、製剤の安定性も良好であった。
一方、ホソバヒカゲスゲ抽出物のみを配合した比較例５では、肌のくすみ改善効果、美白効果、肌のキメ改善効果、ニキビ・吹き出物改善効果は認められるものの、いずれも十分なものではなかった。さらに、アスコルビン酸誘導体のみを含有する比較例６、公知の表皮細胞賦活剤である（−）−エピガロカテキン−３−ガレートを配合した比較例７、８でも、肌のくすみ改善効果、美白効果、肌のキメ改善効果、ニキビ・吹き出物改善効果とも認められなかった。
From the results of Examples 3 and 4, the milky lotion combined with the ascorbic acid derivative according to the present invention is excellent in skin dullness improvement effect, whitening effect, skin texture improvement effect, acne / pimple improvement effect, formulation The stability of was also good.
On the other hand, in Comparative Example 5 in which only the extract of Hosobahikage-gege was blended, the skin dullness improving effect, the whitening effect, the skin texture improving effect, and the acne / pimple improvement effect were recognized, but none of them was sufficient. Furthermore, Comparative Example 6 containing only an ascorbic acid derivative, and Comparative Examples 7 and 8 containing (-)-epigallocatechin-3-gallate, which is a known epidermal cell activator, are also effective in improving skin dullness and whitening. Neither skin texture improvement effect nor acne / breakout improvement effect was observed.
〔実施例５、６、比較例９、１０：官能評価〕
上記のホソバヒカゲスゲ抽出物粉末、アスコルビン酸誘導体を使用して、表４に示すクリームを調製し、実施例１、２と同様の方法により評価を行なった。なお、ホソバヒカゲスゲ抽出物粉末を含有するクリームの調製は、乳液の場合と同様に、ホソバヒカゲスゲ抽出物粉末を表４に示す多価アルコールとノニオン性界面活性剤成分にあらかじめ溶解した後、他の成分に配合することにより行った。結果を表４に示す。
[Examples 5 and 6, Comparative Examples 9 and 10: Sensory evaluation]
Creams shown in Table 4 were prepared using the above-mentioned powdered extract of Aspergillus niger and ascorbic acid derivatives, and evaluated in the same manner as in Examples 1 and 2. In addition, preparation of the cream containing Hosoba lizard extract powder was prepared by dissolving Hosoba lizard extract powder in the polyhydric alcohol and nonionic surfactant components shown in Table 4 in advance, as in the case of the emulsion. This was done by blending with the ingredients. The results are shown in Table 4.
実施例５、６の結果から、本発明によるホソバヒカゲスゲ抽出物とアスコルビン酸誘導体を併用したクリームは、肌のくすみ改善効果、美白効果、肌のキメ改善効果、ニキビ・吹き出物改善効果に優れており、製剤の安定性も良好であった。
一方、ホソバヒカゲスゲ抽出物のみを配合した比較例９では、肌のくすみ改善効果、美白効果、肌のキメ改善効果、ニキビ・吹き出物改善効果は認められるものの、いずれも十分なものではなかった。さらに、アスコルビン酸誘導体のみを含有する比較例１０においては、肌のくすみ改善効果、美白効果、肌のキメ改善効果、ニキビ・吹き出物改善効果はいずれも認められなかった。
From the results of Examples 5 and 6, the cream using the Ascorbic acid derivative in combination with the extract of Ascorbic acid according to the present invention is excellent in skin dullness improvement effect, whitening effect, skin texture improvement effect, acne / pimple improvement effect. The stability of the preparation was also good.
On the other hand, in Comparative Example 9 in which only the extract of Hosoba-Kigekage was blended, the skin dullness improvement effect, the whitening effect, the skin texture improvement effect, and the acne / pimple improvement effect were recognized, but none of them was sufficient. Furthermore, in Comparative Example 10 containing only the ascorbic acid derivative, none of the skin dullness improving effect, the whitening effect, the skin texture improving effect, and the acne / breakout improving effect were observed.
〔総括〕
以上詳述の通り、ホソバヒカゲスゲ抽出物は、従来のものよりも高活性な表皮角化細胞賦活作用を有しており、また高濃度においても賦活活性を示すことが明らかとなった。そのため、ホソバヒカゲスゲ抽出物と、アスコルビン酸またはその誘導体とを含有する皮膚外用剤は、従来の表皮角化細胞賦活剤を含有する皮膚外用剤で認められる肌のくすみ改善効果、美白効果、肌のキメ改善効果よりも単に優れるだけでなく、かかる従来の皮膚外用剤では得られなかったニキビ・吹き出物改善効果をも優位に有しており、安定性も良好であった。
[Summary]
As described above in detail, it has been clarified that the extract of Lilium fountain has a higher activity of keratinocyte activation than that of the conventional one, and also exhibits an activation activity even at a high concentration. Therefore, the external preparation for skin containing Hosoba lizard extract and ascorbic acid or a derivative thereof is a skin dullness improving effect, a whitening effect, a skin whitening effect, and a skin external preparation containing a conventional keratinocyte activator. Not only was it superior to the texture-improving effect, but it also had an effect of improving acne and pimples that could not be obtained with such conventional external preparations for skin, and also had good stability.
本発明の皮膚外用剤は、医薬品、医薬部外品、化粧品類（例えば、化粧水、乳液、クリーム、ジェル、美容液、パック、オイル、軟膏、スプレー、貼付剤など）として利用することができる。 The external preparation for skin of the present invention can be used as pharmaceuticals, quasi drugs, cosmetics (for example, lotion, milky lotion, cream, gel, cosmetic liquid, pack, oil, ointment, spray, patch, etc.). .
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014040542A JP5859587B2 (en) | 2014-03-03 | 2014-03-03 | Topical skin preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014040542A JP5859587B2 (en) | 2014-03-03 | 2014-03-03 | Topical skin preparation |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009260520A Division JP2011105624A (en) | 2009-11-13 | 2009-11-13 | Epidermal keratinocyte-activating agent and external preparation for skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014098052A true JP2014098052A (en) | 2014-05-29 |
| JP5859587B2 JP5859587B2 (en) | 2016-02-10 |
Family
ID=50940330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014040542A Active JP5859587B2 (en) | 2014-03-03 | 2014-03-03 | Topical skin preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5859587B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101729654B1 (en) | 2015-10-20 | 2017-05-11 | 한국과학기술연구원 | An antibacterial composition comprising extracts of carex humilis |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09110628A (en) * | 1995-09-19 | 1997-04-28 | L'oreal Sa | Composition for make-up and/or dermatology containing ascorbic acid as active agent for treating seborrhea |
| JP2000169321A (en) * | 1998-12-03 | 2000-06-20 | Nippon Zetokku Kk | Cell activation agent and preparation for external use for skin and skin cleaning agent containing the activation agent |
| FR2844714A1 (en) * | 2002-09-20 | 2004-03-26 | Af Consulting | Cosmetic, pharmaceutical or food supplement compositions, comprising resveratrol oligomer or derivative, optionally as plant extract, useful for combating hormonal disorders of skin or exoskeleton and effects of age, e.g. wrinkles |
| JP2004182635A (en) * | 2002-12-02 | 2004-07-02 | Rohto Pharmaceut Co Ltd | External skin preparation |
| KR100523753B1 (en) * | 1997-12-23 | 2005-12-28 | 주식회사 엘지생활건강 | Anti-inflammatory composition containing mountain mirror extract |
| FR2898493A1 (en) * | 2006-03-16 | 2007-09-21 | Af Consulting | COSMETIC, PHARMACEUTICAL, FOOD AND VETERINARY COMPOSITIONS WHOSE ACTION ACTIVATION OF SIRTUIN GENES ENABLES DELAYING THE AGING OF MAMMALS AND ITS NEGATIVE EFFECTS |
| KR20080104759A (en) * | 2007-05-29 | 2008-12-03 | 주식회사 바이오랜드 | Composition comprising an extract of carex humilis leyss or alpha;-viniferin compound isolated therefrom for skin whitening |
-
2014
- 2014-03-03 JP JP2014040542A patent/JP5859587B2/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09110628A (en) * | 1995-09-19 | 1997-04-28 | L'oreal Sa | Composition for make-up and/or dermatology containing ascorbic acid as active agent for treating seborrhea |
| KR100523753B1 (en) * | 1997-12-23 | 2005-12-28 | 주식회사 엘지생활건강 | Anti-inflammatory composition containing mountain mirror extract |
| JP2000169321A (en) * | 1998-12-03 | 2000-06-20 | Nippon Zetokku Kk | Cell activation agent and preparation for external use for skin and skin cleaning agent containing the activation agent |
| FR2844714A1 (en) * | 2002-09-20 | 2004-03-26 | Af Consulting | Cosmetic, pharmaceutical or food supplement compositions, comprising resveratrol oligomer or derivative, optionally as plant extract, useful for combating hormonal disorders of skin or exoskeleton and effects of age, e.g. wrinkles |
| JP2004182635A (en) * | 2002-12-02 | 2004-07-02 | Rohto Pharmaceut Co Ltd | External skin preparation |
| FR2898493A1 (en) * | 2006-03-16 | 2007-09-21 | Af Consulting | COSMETIC, PHARMACEUTICAL, FOOD AND VETERINARY COMPOSITIONS WHOSE ACTION ACTIVATION OF SIRTUIN GENES ENABLES DELAYING THE AGING OF MAMMALS AND ITS NEGATIVE EFFECTS |
| KR20080104759A (en) * | 2007-05-29 | 2008-12-03 | 주식회사 바이오랜드 | Composition comprising an extract of carex humilis leyss or alpha;-viniferin compound isolated therefrom for skin whitening |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101729654B1 (en) | 2015-10-20 | 2017-05-11 | 한국과학기술연구원 | An antibacterial composition comprising extracts of carex humilis |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5859587B2 (en) | 2016-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103025310A (en) | Cyclohexyl carbamate compounds as skin and/or hair lightening actives | |
| EP2370052A1 (en) | Novel sebum secretion inhibitory agent | |
| KR20110036682A (en) | COMPOSITIONS COMPRISING AN NFκB-INHIBITOR AND A NON-RETINOID COLLAGEN PROMOTER | |
| US20220079870A1 (en) | Topical skincare compositions comprising centella asiatica | |
| JP5736737B2 (en) | Epidermal keratinocyte activator | |
| US11491102B2 (en) | Composition for skin anti-inflammation and skin moisturizing comprising artemisia extract extracted with skin cosmetic solution as a solvent | |
| KR102015173B1 (en) | Low irritating cosmetic composition for skin whitening | |
| JP2006052198A (en) | Deodorant, deodorant preparation and method of deodorizing treatment of fiber | |
| JP2013018734A (en) | Hyaluronic acid production promoter | |
| KR20200026113A (en) | Topical compositions comprising pichia anomala and retinol | |
| EP2801391B1 (en) | Compositions comprising extracts of Bursera simaruba | |
| JP5859587B2 (en) | Topical skin preparation | |
| KR20200026112A (en) | Topical compositions comprising pichia anomala and n-acetyl glucosamine | |
| KR100678864B1 (en) | Cosmetic composition for skin whitening comprising cnidium officinale extract and carnitine as active ingredient | |
| JP2011105624A (en) | Epidermal keratinocyte-activating agent and external preparation for skin | |
| JP2000344630A (en) | Hair grower raw material and its purification and hair grower composition | |
| TWI687237B (en) | Use of extract of victoria cruziana for inducing expression of keratin gene and hyaluronan synthase 2 gene, and enhancing moisture-retaining capacity of skin | |
| JP2013166732A (en) | Method for producing endothelin activity inhibitor and method for producing usnea longissima extract | |
| JP5602416B2 (en) | Hyaluronidase activity inhibitor | |
| JP7246125B2 (en) | Epidermal cell activator | |
| JP2013166731A (en) | Endothelin activity inhibitor and whitening agent | |
| KR102513929B1 (en) | Functional comsmetics materials having composition and composition ratio for skin elasticity, Manufacturing method thereof and Comsmetics for skin care | |
| WO2022092124A1 (en) | Matrix metalloprotease 1 expression inhibitor, skin external agent, and use for inhibition of matrix metalloprotease 1 expression | |
| KR102078844B1 (en) | Herbal shampoo composition comprising extract from scilla scilloides | |
| JP2010241715A (en) | Neutral endopeptidase inhibitor and hair growth inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140314 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150602 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150803 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151208 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151216 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5859587 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |